You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The funds will help commercialize Ador's NATlab reader, a point-of-care MDX platform for sample-to-answer identification of specific infectious diseases.
The firm said it raised €55.5 million to fund the expansion of its Idylla test platform, its sales and marketing activities, and other general corporate purposes.
The Boston-based startup will use the funds to expedite prototype development of its sample preparation technology and computational approach.
The financing will go toward continued development of its MultiPath technology to rapidly identify hospital infections and determine their antibiotic susceptibility.
During the year, the growing threat of antimicrobial resistance drove development and adoption of advanced diagnostic tests, including molecular testing.
The firm noted that it has already borrowed $350 million under the revolving credit facility. The funds may be used for general corporate and other purposes.
The company also said that it received ISO 13485:2016 certification for its Mosaiq platform and it has filed for CE marking for its initial immunohematology microarray.
The company, established as a merger between A*STAR MedTech spin-off MiRXES and venture capital firm Venturecraft, has developed a blood test for early-stage stomach cancer.
The company has also achieved a CE-IVD mark for its HemeAccuTest, which targets hematological malignancies.
The firm will use the financing to commercialize a test that utilizes metabolomic and DNA biomarkers to characterize obesity and guide weight loss.